Skip to main content
. 2022 Feb 24;6:e2100312. doi: 10.1200/PO.21.00312

FIG 1.

FIG 1.

Subject-level prevalence for composite precision medicine opportunities, including actionable PGx, management of serious CYP-mediated DDIs, and management of DDIs including acid reducers and TKIs. CYP, cytochrome P450; DDI, drug-drug interaction; PGx, pharmacogenetics; TKI, tyrosine kinase inihibitors.